| Cherry Blossom Intimates | |
| 9201 Woodmore Center Dr, Ste 426, Glenarden, Maryland 20706 | |
| (301) 580-0059 |
| Name | Cherry Blossom Intimates |
|---|---|
| Organization Name | Cherry Blossom Intimates Inc |
| Location | 9201 Woodmore Center Dr, Ste 426, Glenarden, Maryland 20706 |
| Type | Supplier |
| Phone | (301) 580-0059 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
pSivida Corp., a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences has been notified that the U.S. Food and Drug Administration (FDA) has granted Priority Review status for the New Drug Application (NDA) filed for Iluvien for the treatment diabetic macular edema (DME).
With a new $3 million grant from the National Institutes of Health, Cedars-Sinai Heart Institute investigators are moving closer to their goal of developing a biological pacemaker that can treat patients afflicted with slow heartbeats.
In a groundbreaking new study from UC San Francisco, researchers have found that children affected with sensory processing disorders (SPD) have quantifiable differences in brain structure, showing a biological basis for the disease that sets it apart from other neurodevelopmental disorders.
A report just released by Cogent Research, in partnership with CAHG, reveals that Americans are more concerned than ever about the privacy of their genetic information. Furthermore, this concern is increasingly inhibiting the likelihood that they will consider having a molecular diagnostic test. These and other findings are explored in more detail in the 5th edition of the Cogent Genomics, Attitudes & Trends study (CGAT 2010).
The groin is the usual access point for investigating or treating the heart with a catheter, but using the wrist as access point reduces bleeding and lowers mortality. These findings are from an international study with major involvement from the University of Bern published today in the Lancet.
› Verified 2 days ago
News Archive
pSivida Corp., a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences has been notified that the U.S. Food and Drug Administration (FDA) has granted Priority Review status for the New Drug Application (NDA) filed for Iluvien for the treatment diabetic macular edema (DME).
With a new $3 million grant from the National Institutes of Health, Cedars-Sinai Heart Institute investigators are moving closer to their goal of developing a biological pacemaker that can treat patients afflicted with slow heartbeats.
In a groundbreaking new study from UC San Francisco, researchers have found that children affected with sensory processing disorders (SPD) have quantifiable differences in brain structure, showing a biological basis for the disease that sets it apart from other neurodevelopmental disorders.
A report just released by Cogent Research, in partnership with CAHG, reveals that Americans are more concerned than ever about the privacy of their genetic information. Furthermore, this concern is increasingly inhibiting the likelihood that they will consider having a molecular diagnostic test. These and other findings are explored in more detail in the 5th edition of the Cogent Genomics, Attitudes & Trends study (CGAT 2010).
The groin is the usual access point for investigating or treating the heart with a catheter, but using the wrist as access point reduces bleeding and lowers mortality. These findings are from an international study with major involvement from the University of Bern published today in the Lancet.
› Verified 2 days ago
Cherry Blossom Intimates Type: Medicare Supplier Location: 9201 Woodmore Center Dr, Glenarden, Maryland 20706 Phone: (301) 580-0059 |